@article{10902/36639,
year = {2025},
url = {https://hdl.handle.net/10902/36639},
abstract = {This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), including those with complex karyotype, MECOM (EVI1) rearrangement, or TP53 mutations/del(17p), and an additional adverse group (Adv*). The study included 651 AML patients treated with at least one line of anthracycline-based induction therapy and in complete remission. According to the Allo-HCT Refined ELN 2022 risk classification, 19.4% (n = 126) patients were classified into the Favorable (Fav) risk, 38.1% (n = 248) into the Intermediate (Int) risk, 27.2% (n = 177) in the Adv* and 15.4% (n = 100) in the AdvP. Outcomes were significantly poorer for patients allocated in the AdvP risk group (5-year OS rate: 32.3%, 5-year LFS rate: 24.3%, both p < 0.001 with the rest of subgroups) and a higher CIR (5-year CIR: 64.3%, p < 0.001). Patients in the Adv* risk group had similar outcomes than patients in the Int risk group (5-year OS rate: 70.2% vs. 66.7%, p = 0.69, 5-year LFS rate: 63.8% vs. 55.9%, p = 0.33). Multivariate analysis confirmed the dismal outcomes for AdvP patients for OS: Hazard Ratio (HR) = 3.05, and LFS: HR = 2.66, both p < 0.001. Our findings validate the Allo-HCT Refined ELN 2022 classification as a robust prognostic tool, particularly highlighting the poor outcomes for the AdvP subgroup.},
organization = {We thank our patients and the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) for the support provided during the study development. In addition, Dr. Jordi Esteve and María Jesús Pascual Cascón for their mentorship and support during the study period. We additionally thank REDCap (Research Electronic Data Capture) service for permitting the use of their service without costs. REDCap is a secure, web-based software platform designed to support data capture for research studies.},
publisher = {Nature Pub. Group},
publisher = {Blood Cancer Journal, 2025, 15(1), 42},
title = {Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)},
author = {Jiménez Vicente, Carlos and Esteve, Jordi and Baile González, Mónica and Pérez López, Estefanía and Martin Calvo, Carmen and Aparicio, Clara and Oiartzabal Ormategi, Itziar and Esquirol, Albert and Peña Muñoz, Felipe and Fernández Luis, Sara and Heras Fernando, Inmaculada and González Rodríguez, Ana Pilar and López García, Alberto and López Lorenzo, Jose Luis and Torrado, Tamara and Sáez Marín, Adolfo Jesús and Acosta Fleytas, Cynthia and García, Lucía and Villar, Sara and Filaferro, Silvia},
}